Description: Pharmaxis Ltd is a research pharmaceutical company with a portfolio of products at various stages of development and approval. The Company is engaged in research, development and commercialization of human healthcare products for the treatment and management of chronic diseases. Its segments include Bronchitol and Aridol, which covers the ongoing clinical development, manufacture and sale of the Bronchitol and Aridol across the globe; New Drug Development, which encompasses the drug discovery and early-stage clinical development of its new drug candidates, and Corporate. The Company's development pipeline is focused on amine oxidase chemistry and includes Semicarbazide‐Sensitive Amine Oxidase Inhibitors (SSAO) for Non‐alcoholic Steatohepatitis (NASH) and inflammatory diseases, including kidney fibrosis and chronic obstructive pulmonary disease (COPD), and lysyl oxidase inhibitors (LOX) targeting fibrotic diseases, including NASH, pulmonary fibrosis and some cancers.
Home Page: www.pharmaxis.com.au
PXS Technical Analysis
Pax World Funds Series Trust I
,
Phone:
800-372-7827
Officers
| Name | Title |
|---|---|
| Mr. Gary Jonathan Phillips BPharm, MBA | CEO, MD & Director |
| Mr. David Morris McGarvey BA, CA, CPA | CFO & Company Sec. |
| Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. | Head of Drug Discovery |
| Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin | Head of Medical & Regulatory Affairs - Alliance Management |
| Dr. Jana Baskar | Chief Medical Officer |
| Mr. Cameron David Billingsley | Gen. Counsel |
| Dr. Dieter Hamprecht | Head of Chemistry for Drug Discovery |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 20.4499 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9926 |
| Price-to-Sales TTM: | 2.3256 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 65 |